← Organon & Co.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Net Income $2.2b
$3.2b +49.47%
$2.2b -32.88%
$1.4b -37.45%
$917.0m -32.12%
$1.0b +11.56%
$864.0m -15.54%
$187.0m -78.36%
$209.0m +11.76%
Depreciation $49.0m $49.0m $56.0m $92.0m $96.0m $120.0m $132.0m $156.0m $159.0m
Amortization $284.0m $284.0m $86.0m $103.0m $116.0m $116.0m $145.0m $205.0m $195.0m
Depreciation Amortization Depletion $1.7b $354.0m $157.0m — $212.0m $236.0m $277.0m $361.0m $354.0m
Deferred Income Tax Expense (Benefit) — $12.0m ($32.0m) ($288.0m) ($18.0m) ($485.0m) ($160.0m) $63.0m $89.0m
Deferred Tax — — — — ($18.0m) ($485.0m) ($160.0m) $63.0m $89.0m
Share-based Payment Arrangement, Noncash Expense — — $40.0m $59.0m $75.0m $101.0m $105.0m $77.0m $75.0m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — $11.0m $17.0m $22.0m $15.0m —
Share-based Payment Arrangement, Expense — — $40.0m $59.0m $75.0m $101.0m $105.0m $77.0m $75.0m
Stock-based compensation $56.0m $41.0m $40.0m $59.0m $75.0m $101.0m $105.0m $77.0m $75.0m
Employee withholding taxes related to stock-based awards — — $0 $0 ($11.0m) ($17.0m) ($22.0m) ($15.0m) —
Goodwill, Impairment Loss — — — — — — — $301.0m $301.0m
Impairment of Intangible Assets, Finite-lived — — — $7.0m $9.0m — $0 $9.0m —
Impairment of assets — $0 $0 $7.0m $9.0m $0 $0 $9.0m —
Impairment of Goodwill — — — — — $0 $0 $301.0m —
Asset Impairment Charge — — — — $9.0m $0 $0 $310.0m $301.0m
Changes in operating assets and liabilities:
Change In Working Capital — — — — ($452.0m) ($155.0m) ($278.0m) ($247.0m) ($144.0m)
Increase (Decrease) in Accounts Receivable $250.0m $200.0m $13.0m $277.0m $123.0m $212.0m ($383.0m) ($79.0m) ($21.0m)
Accounts receivable $250.0m $200.0m $13.0m ($277.0m) ($123.0m) ($212.0m) $383.0m $79.0m ($21.0m)
Change In Receivables — — — — ($123.0m) ($212.0m) $383.0m $79.0m ($21.0m)
Changes In Account Receivables — — — — ($123.0m) ($212.0m) $383.0m $79.0m ($21.0m)
Increase (Decrease) in Inventories $44.0m ($91.0m) $34.0m $138.0m $220.0m $230.0m $131.0m $13.0m ($6.0m)
Inventories $44.0m ($91.0m) $34.0m ($138.0m) ($220.0m) ($230.0m) ($131.0m) ($13.0m) ($6.0m)
Change In Inventory $44.0m ($91.0m) $34.0m — ($220.0m) ($230.0m) ($131.0m) ($13.0m) ($6.0m)
Trade accounts payable $20.0m ($35.0m) $37.0m $663.0m ($237.0m) $163.0m ($157.0m) ($217.0m) —
Change In Payables And Accrued Expense ($170.0m) ($86.0m) $12.0m — ($58.0m) $281.0m ($323.0m) ($420.0m) ($2.0m)
Accrued and other current liabilities ($170.0m) ($86.0m) $12.0m $329.0m $172.0m $102.0m ($101.0m) ($142.0m) —
Change In Accrued Expense ($170.0m) ($86.0m) $12.0m — $172.0m $102.0m ($101.0m) ($142.0m) ($8.0m)
Other — $35.0m ($20.0m) $55.0m ($8.0m) $16.0m $29.0m $139.0m —
Other current assets — ($105.0m) $80.0m $353.0m ($43.0m) ($10.0m) ($236.0m) ($32.0m) ($45.0m)
Net Cash Provided by Operating Activities $3.7b
$2.8b -24.95%
$2.2b -20.96%
$2.5b +12.39%
$917.0m -62.69%
$1.0b +11.56%
$939.0m -8.21%
$700.0m -25.45%
$737.0m +5.29%
Capital Expenditures ($101.0m) ($109.0m) ($278.0m) $192.0m $196.0m $251.0m $175.0m $162.0m ($303.0m)
Proceeds from sale of property, plant and equipment $32.0m $4.0m $5.0m $7.0m $7.0m $1.0m $4.0m $1.0m $0
Capital Expenditure Reported — — — — ($196.0m) ($251.0m) ($175.0m) ($162.0m) ($303.0m)
Net Cash Used in Investing Activities ($69.0m) ($102.0m) ($258.0m) $0 ($420.0m) ($260.0m) ($513.0m) ($390.0m) $130.0m
Proceeds from Issuance of Long-term Debt — — $0 $9.5b $0 $80.0m $1.2b $1.1b $625.0m
Proceeds from debt — $0 $0 $9.5b $0 $80.0m $1.2b $1.1b —
Payment of long-term debt issuance costs — $0 $0 ($118.0m) $0 $0 ($38.0m) $0 —
Issuance Of Debt — — — — $0 $80.0m $1.2b $1.1b $625.0m
Long Term Debt Issuance — — — — $0 $80.0m $1.2b $1.1b $625.0m
Net Issuance Payments Of Debt — — — — ($108.0m) ($258.0m) ($11.0m) ($458.0m) ($286.0m)
Net Long Term Debt Issuance — — — — ($108.0m) ($258.0m) ($11.0m) ($458.0m) ($286.0m)
Net Short Term Debt Issuance — — — ($1.5b) $0 $0 — — —
Short Term Debt Issuance — — — $0 $0 — — — $0
Repayments of Long-term Debt — — $0 $112.0m $108.0m $338.0m $1.2b $1.5b ($911.0m)
Gain on debt repurchase — — — — — $0 $0 ($73.0m) —
Repayments of debt — $0 $0 ($112.0m) ($108.0m) ($338.0m) ($1.2b) ($1.5b) ($911.0m)
Long Term Debt Payments — — — — ($108.0m) ($338.0m) ($1.2b) ($1.5b) ($911.0m)
Repayment Of Debt — — — — ($108.0m) ($338.0m) ($1.2b) ($1.5b) ($911.0m)
Short Term Debt Payments — — — ($1.5b) $0 $0 — — —
Common Stock Dividend Paid — — — — ($290.0m) ($294.0m) ($297.0m) ($88.0m) ($18.0m)
Dividends paid — — $0 $145.0m $290.0m $294.0m $297.0m $88.0m ($18.0m)
Dividend payments — $0 $0 ($145.0m) ($290.0m) ($294.0m) ($297.0m) ($88.0m) —
Cash Dividends Paid — — — — ($290.0m) ($294.0m) ($297.0m) ($88.0m) ($18.0m)
Net Other Financing Charges — — — — ($35.0m) ($17.0m) ($60.0m) ($15.0m) ($9.0m)
Net Cash Used in Financing Activities ($4.2b)
($2.6b) +37.06%
($2.2b) +17.02%
($356.0m) +83.63%
($433.0m) -21.63%
($569.0m) -31.41%
($368.0m) +35.33%
($561.0m) -52.45%
($313.0m) +44.21%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — ($249.0m) $667.0m ($31.0m) ($13.0m) ($18.0m) ($101.0m) $1.2b
Cash and Cash Equivalents at Beginning of Period $771.0m $244.0m $319.0m $737.0m $737.0m $706.0m $693.0m $675.0m —
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — $0 $23.0m ($36.0m) $17.0m ($76.0m) $150.0m ($21.0m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — $12.0m $737.0m $706.0m $693.0m $675.0m $574.0m $1.2b
Effect of Exchange Rate Changes on Cash and Cash Equivalents — $0 $0 $23.0m ($36.0m) $17.0m ($76.0m) $150.0m ($21.0m)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent — — $2.3b $1.4b $917.0m $1.0b — — —
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent — — ($96.0m) $0 $0 $0 — — —
Income Tax Expense (Benefit) — — $496.0m $178.0m $205.0m ($350.0m) ($57.0m) $238.0m —
Additional Financial Items
Foreign Currency Transaction Gain (Loss), before Tax — — $5.0m ($18.0m) ($11.0m) ($42.0m) ($26.0m) ($14.0m) —
Foreign Currency Transaction Gain (Loss), Unrealized — — — — $18.0m ($40.0m) $2.0m $21.0m —
Goodwill — — $4.6b $4.6b $4.6b $4.6b $4.7b $4.2b $301.0m
Acquired in-process research and development and milestones — — $0 ($104.0m) ($107.0m) ($8.0m) ($71.0m) ($30.0m) —
Accretion and changes in fair value in contingent consideration — — — — — $0 $11.0m ($50.0m) —
Unrealized foreign exchange (gain) loss — $0 ($5.0m) $18.0m ($18.0m) $40.0m ($2.0m) ($21.0m) —
Income taxes payable ($166.0m) ($590.0m) ($118.0m) ($119.0m) $7.0m $16.0m ($65.0m) ($61.0m) —
Dermavant acquisition, net of cash acquired — — — — $0 $0 ($166.0m) ($75.0m) —
Purchase of product rights and asset acquisition — $0 $0 ($192.0m) ($124.0m) ($2.0m) ($105.0m) ($124.0m) —
Cash Flow From Continuing Financing Activities — — — — ($433.0m) ($569.0m) ($368.0m) ($561.0m) ($313.0m)
Cash Flow From Continuing Investing Activities — — — — ($420.0m) ($260.0m) ($513.0m) ($390.0m) $130.0m
Cash From Discontinued Financing Activities — — — ($356.0m)
$0 +100.00%
— — — —
Cash From Discontinued Investing Activities — — — ($356.0m) $0 $0 — — —
Change In Account Payable — — — — ($237.0m) $163.0m ($157.0m) ($217.0m) ($2.0m)
Change In Payable — — — — ($230.0m) $179.0m ($222.0m) ($278.0m) ($2.0m)
Change In Tax Payable — — — — $7.0m $16.0m ($65.0m) ($61.0m) ($104.0m)
Changes In Cash — — — — $5.0m ($30.0m) $58.0m ($251.0m) $554.0m
Cash and Cash Equivalents at End of Period $244.0m $319.0m $70.0m — $706.0m $693.0m $675.0m $574.0m —
Free Cash Flow — — — — $431.0m $538.0m $588.0m $384.0m $434.0m
Net Business Purchase And Sale — — — — $0 $0 ($166.0m) ($75.0m) $433.0m
Net Foreign Currency Exchange Gain Loss — — — — ($18.0m) $40.0m ($2.0m) ($21.0m) ($31.0m)
Net Intangibles Purchase And Sale — — — — ($231.0m) ($10.0m) ($176.0m) ($154.0m) ($133.0m)
Net PPE Purchase And Sale — — — — $7.0m $1.0m $4.0m $1.0m $0
Operating Gains Losses — — — — ($18.0m) $40.0m ($2.0m) ($94.0m) ($139.0m)
Other Cash Adjustment Outside Changein Cash — — — $0 $0 $0 — — —
Other Non Cash Items — — — — $133.0m $39.0m $133.0m $43.0m —
Purchase Of Business — — — — $0 $0 ($166.0m) ($75.0m) $0
Purchase Of Intangibles — — — — ($231.0m) ($10.0m) ($176.0m) ($154.0m) ($133.0m)
Sale Of PPE — — — — $7.0m $1.0m $4.0m $1.0m $0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement — — — — — — ($1.0m) $0 —
Derivative, Gain (Loss) on Derivative, Net — — — — $0 $0 — — —
Net Decrease in Cash and Cash Equivalents — $75.0m ($249.0m) $667.0m ($31.0m) ($13.0m) ($18.0m) ($101.0m) —
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — ($31.0m) ($13.0m) ($18.0m) ($101.0m) —
Income Taxes Paid, Net — — — — — — — $287.0m —

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.